GLMD

Business Context and Reporting Period

Company: Galmed Pharmaceuticals Ltd. (GLMD)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Galmed is a biopharmaceutical company focused on developing Aramchol, a first-in-class oral SCD1 modulator. Historically focused on Non-Alcoholic Steatohepatitis (NASH), the company has discontinued the open-label part of its Phase 3 ARMOR Study and is now pivoting to advance Aramchol for oncological indications (specifically gastrointestinal cancers) in combination with standard-of-care agents. The company has no approved products and has not generated revenue from product sales.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by approximately 37% to $10.3 million in 2025 from $7.5 million in 2024. This was driven by higher R&D expenses and a significant impairment charge.
• R&D Expense Growth: R&D expenses rose 64% to $4.9 million, primarily due to increased clinical trial expenses ($1.1 million increase) and pre-clinical studies ($0.6 million increase) related to the new oncology strategy.
• Impairment Charge: The company recorded a full write-off of approximately $2.5 million related to its investment in OnKai, Inc. and an associated loan. OnKai filed for dissolution in December 2025, rendering the investment unrecoverable.
• Capital Raising: The company significantly increased its share count (from ~1.66M to ~6.58M) through a Standby Equity Purchase Agreement (SEPA) and an At-The-Market (ATM) facility, raising approximately $9.0 million in net proceeds from financing activities.

Guidance, Outlook, and Risks

Strategic Pivot: Galmed is no longer pursuing the Phase 3 ARMOR Study for NASH. Instead, it is advancing Aramchol for oncological indications (hepatocellular carcinoma, cholangiocarcinoma, colorectal cancer) in combination with standard-of-care agents like Stivarga (regorafenib). A Phase 1/2 clinical trial is planned for H2 2026.

Liquidity and Going Concern:

• Management has concluded there is substantial doubt about the company's ability to continue as a going concern.
• The independent auditor included an explanatory paragraph regarding this doubt in the audit report.
• Current cash and liquid assets (~$18.3 million) are estimated to support operations for more than 12 months from the report date, but significant additional funding is required for future development.

Key Risks:

• Regulatory Uncertainty: Significant uncertainty remains regarding the regulatory pathway for NASH drugs and the success of the new oncology trials.
• Capital Requirements: The company is subject to the "Baby Shelf Rule" due to a low public float (~$3.8 million as of March 2026), limiting its ability to raise funds via primary public offerings until the float exceeds $75 million.
• Geopolitical Risk: Operations are based in Israel, exposing the company to risks from regional conflict, military reserve call-ups, and economic instability.
• Delisting Risk: The company's market value of listed securities is below $5 million, creating a risk of immediate suspension or delisting from Nasdaq under proposed rule changes.

Investor Verification Checklist

• Going Concern Status: Verify the company's ability to secure additional financing beyond the current 12-month runway, given the auditor's "substantial doubt" qualification.
• Capital Raising Constraints: Confirm the impact of the "Baby Shelf Rule" on the company's ability to raise equity capital efficiently.
• Strategic Execution: Monitor the initiation and progress of the planned Phase 1/2 oncology trials scheduled for H2 2026.
• Nasdaq Compliance: Track the company's market capitalization and share price to assess the risk of delisting from the Nasdaq Capital Market.
• OnKai Write-off: Confirm that the $2.5 million impairment charge related to OnKai is fully recognized and no further liabilities exist.